Inclusion Criteria:

1. Pathologically confirmed diagnosis of a solid tumor for which no standard therapy proven to provide clinical benefit is available.
2. ≥18 years of age at the time of signing the informed consent.
3. Life expectancy of at least 3 months.
4. An Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.

Exclusion Criteria:

1. Inadequate hematologic function defined by absolute neutrophil count (ANC) <1,500 cells/mm3, platelet count <100,000/mm3, or hemoglobin <9.0 g/dL (may be increased to this level with transfusion as long as there is no evidence of active bleeding).
2. Inadequate hepatic function defined by aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) >2.5 x upper limit of normal (ULN); >5 x ULN if attributable to liver metastases; total bilirubin >1.5 x ULN.
3. Inadequate renal function defined by serum creatinine >1.5 x ULN.
4. Uncontrolled hypomagnesemia or hypokalemia, defined as ≥ Grade 3 despite adequate electrolyte supplementation.
5. Patients with a history of stroke, unstable angina, myocardial infarction, or ventricular arrhythmia requiring medication or mechanical control within the last 6 months.
6. History of a seizure within the last 10 years or seizure disorder requiring anti-epileptic medications.
7. History of brain metastases or primary brain tumor.
8. Significant co-morbid condition or disease which in the judgment of the Investigator would place the patient at undue risk or interfere with the study.
9. Pregnant or lactating women.